《现代医学与健康研究》编辑部官网!【中国医师协会系列期刊】
卡培他滨不同剂量用于晚期消化道肿瘤 对患者肿瘤标志物的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R735

基金项目:


Effects of different doses of Capecitabine on tumor markers in patients with advanced gastrointestinal tumors
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨卡培他滨不同剂量用于晚期消化道肿瘤对患者癌胚抗原(CEA)、糖类抗原 125(CA125)、糖类抗原 724 (CA724)、糖类抗原 199(CA199)的影响,为临床治疗该病提供参考依据。方法 以随机数字表法将 2018 年 1 月至 2021 年 1 月 期间在苏州工业园区星海医院治疗的 62 例晚期消化道肿瘤患者分为对照组(31 例,2 500 mg/m2 卡培他滨治疗)与试验组(31 例, 2 000 mg/m2 卡培他滨治疗),3 周为 1 个疗程,两组患者均治疗 3 个疗程。比较治疗后两组患者临床疗效,治疗前后血清 CEA、CA125、 CA724、CA199 水平,生存质量评分,治疗期间不良反应发生情况,以及随访 1 年生存率。结果 治疗后两组患者血清 CEA、CA125、 CA724、CA199 水平与治疗前比均显著降低;而生命质量测定量表(FACT-G)各项评分均显著高于治疗前,治疗期间试验组患者恶心 呕吐、口腔炎、白细胞下降、色素沉着、手足综合征发生率均显著低于对照组(均P<0.05);但治疗后两组间临床客观缓解率、血清 CEA、CA125、CA724、CA199 水平、社会状况、情感状况、功能状况、生理状况评分及随访 1 年时生存率比较,差异均无统计学意义 (均P>0.05)。结论 不同剂量的卡培他滨治疗晚期消化道肿瘤,可降低患者肿瘤标志物水平,改善生存质量,疗效确切;但是相比 2 500 mg/m2 的使用剂量,应用 2 000 mg/m2 的卡培他滨治疗,患者的不良反应较少,安全性更高。

    Abstract:

    Objective To analyze the effects of different doses of Capecitabine on carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 724 (CA724) and carbohydrate antigen 199 (CA199) in patients with advanced gastrointestinal tumors, so as to provide reference for clinical treatment. Methods? A total of 62 patients with advanced gastrointestinal tumors who were treated in Suzhou Industrial Park Xinghai Hospital from January 2018 to January 2021 were divided into control group (31 cases, treated with 2 500 mg/m2 Capecitabine) and experimental group (31 cases, treated with 2 000 mg/m2 Capecitabine) by random number table methods, 3 weeks for a course of treatment, patients in both groups were received 3 courses of treatment. Clinical efficacy of patients after treatment, serum CEA, CA125, CA724, CA199 levels before and after treatment, quality of life score, adverse reactions during treatment and 1-year survival rate were compared between the two groups. Results? After treatment, the serum levels of CEA, CA125, CA724 and CA199 in the two groups were significantly lower than those before treatment; the functional assessment of cancer therapy general (FACT-G) scores were significantlyhigher than those before treatment, during the treatment period, the incidences of nausea and vomiting, stomatitis, leukopenia, pigmentation and hand-foot syndrome in the experimental group were significantly lower than those in the control group (all P<0.05); however, after treatment, there were no significant differences in the clinical objective remission rate, levels of serum CEA, CA125, CA724, CA199, scores of social status, emotional status, functional status, physiological status and survival rate at 1-year follow-up between the two groups (all P>0.05). Conclusion? Different doses of Capecitabine in the treatment of advanced gastrointestinal tumors can reduce the level of tumor markers in patients, improve the quality of life, and have definite curative effect; however, compared with the dose of 2 500 mg/m2 , the use of Capecitabine at 2 000 mg/m2 has fewer adverse reactions and higher safety.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-09-08
  • 出版日期:

地址:北京朝阳区北沙滩1号16信箱

邮编:100083

电话:010-64882183 64883630

E-mail:xdyx2020@vip.163.com


温馨提示:建议您使用Chrome80、火狐74+、IE11浏览器 ,当您的浏览器版本过低,可能会影响部分功能正常使用。

现代医学与健康研究 ® 2024 版权所有

技术支持:北京勤云科技发展有限公司